

NIFTY KEY LEVELS

Support 1: 9250 Support 2: 9140 Resistance1: 9400 Resistance2: 9550

Events Today

Results

HEXAWARE

Dividend

BRITANNIA

Ex-Date: 29-04-2020



Market Outlook

Yesterday, Nifty opened positive at 9389.80 and made a low of 9260.00. From there it moved towards the high of 9404.40 and closed positive at 9380.90 levels. On sectoral front PSU BANK, AUTO, MEDIA, PVT BANK, IT, FIN SERVICE and REALTY traded with positive bias, whereas PHARMA, FMCG and METAL. India VIX closed negative by 7.60% at 35.14.

Formation of dragon fly doji suggest indecisiveness among market participants but it also indicates that Bulls are still having power to extend this pullback further. On sustaining above 9400 mark, it can extend up to 9550 levels. Support will remain same at 9250 level followed by 9140 levels.

Indian Market				
Index (Prev. Close)	Value	% Change		
SENSEX	32,114.52	1.17%		
NIFTY	9,380.90	1.06%		
BANK NIFTY	20,671.10	2.94%		
Global	Market			
Index (Prev. Close)	Value	% Change		
DOW	24,101.55	-0.13%		
NASDAQ	8,607.73	-1.40%		
CAC	4,569.79	1.43%		
DAX	10,795.63	1.27%		
FTSE	5,958.50	1.91%		
EW ALL SHARE	15,746.78	0.52%		
Morning Asian Market (8	:30 am)			
SGX NIFTY	9,433.00	0.41%		
NIKKIE	19,771.19	-0.06%		
HANG SENG	24,695.75	0.49%		
Commodi	ty Market			
Commodity(Prev. Close)	Value	% Change		
GOLD	46,066.00	-0.27%		
SILVER	41,712.00	-0.58%		
CRUDEOIL	23.68	3.91%		
NATURALGAS	149.60	3.24%		
Currency Market				
Currency (Prev. Close)	Value	% Change		
RS./DOLLAR	76.18	-0.07%		
RS./EURO	82.68	0.01%		
RS./POUND	94.99	0.28%		

Bond Yield			
Bond yield (Prev. Close)	Val	ue	% Change
G-sec 10YR : IND	6.	14	-0.26%

% Change in 1 day

Institutional Turnover						
FII						
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)			
28-Apr-20	4878	5000	(122)			
Apr-20	107957	(7900)				
2020	485568	577381	(91813)			
DII						
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)			
28-Apr-20	4250	3861	389			
Apr-20	64135	65618	(1482)			
2020	412435	336803	75632			

Quote of the Day: "Spend each day trying to be a little wiser than you were when you woke up



AXISBANK BUY 29-Apr-20

Loan book Growth for the bank was resilient among the tough time for the industry, Liability franchise also grew strong. Asset quality during the quarter improved with lower slippages. The NII growth was strong backed by improving NIM. Profitability was impacted on account of the additional provisions worth Rs 3000 Cr made towards the COVID19. The PCR of the banks stands at 69% up from 62% in FY19. Bank has healthy Tier 1 of around 17.5% which can be used for growth however management has guided amid the uncertain circumstances they would look for capital conservation rather than chasing the growth. Going forward into FY21 the profitability of the bank is expected to be impacted on account of Higher provisioning requirements and lower fee income. The stock is currently trading at 1.51XFY20BV.We maintain BUY with TP of 586

MINDTREE ACCUMULATE 28-Apr-20

Mind tree exited FY20 with better revenue and margin performance.4Q revenue came at 1.9% with the highest ever deal win(USD393million in 4Q) despite Covid crisis. Even margin improved steadily (179bps)for last 3 quarters reflecting new leadership strategy working in right direction .Going forward we expect mind tree to be better placed among Mid cap in medium term primarily with strong growth visibility in Hi tech and CPG , Healthy pipeline & ramp up of large deal win(FY20 TCV stood at 1.2billion) and better operational execution. However since the company has some exposure in Travel & Hospitality (16.2% of rev).which will drag growth in near term. Post result, seeing the strong deal closure we have revised our target price from Rs 753 to 945. Thus we valued the stock with revised target price of Rs 945 and Recommend Accumulate.

AMBUJACEM NEUTRAL 28-Apr-20

AMBUJACEM volumes de-grew by 7% YoY with realization growth of 2.4% QoQ. However, the volumes in the last week of 1QCY20 remained impacted due to shut down of factories nationwide. The company has started its operation on a limited capacity in several plants but demand, supply chain and labor availability still remains the concern. On a medium term we expect demand to remain concern due to closure of all economic activities while prices are expected to remain in the same level for at least few months. On Capacity expansion front (4.5 MTPA at Marwar, Mundwa, Rajasthan) the company may delay the commercial production as the existing capacity will remain unutilized due to prevailing situation. On Margin front, the company's continuous thrust on running the plants efficiently, fossil fuel substitution with alternative fuel and emphasis on reducing logistic cost through supply chain efficiency will ensure savings from power & fuel and freight cost which will further contribute in improving EBITDA margin; Thus, we remain positive on the stock. However, considering the current scenario of lockdown and increasing rate of spread of disease, we expect the lockdown to extend which will hamper demand further. Thus, maintain our NEUTRAL rating with a target price of Rs. 190

INDUSINDBANK NEUTRAL 28-Apr-20

Moderation in loan growth continued during the quarter along with the deterioration of asset quality on account of the elevated slippages from the stressed sectors. The NII growth was strong led by improvement in NIM with reduction in the cost of funds. During the quarter bank witnessed withdrawal of deposits by the state government which led in sequential fall of deposits. The management has guided for moderation in corporate loan growth. The exposure to stressed sectors like telecom and microfinance might require heavy provisioning thus denting the profitability. The stock is currently trading at 0.83XFY20BV. We maintain Neutral with TP of 547.

APLLTD ACCUMULATE 24-Apr-20

APLLTD continued to grow strongly in 4QFY20 largely driven by robust growth in US and India partly offset by weak API. Being in the essential services sector, the company has been least impacted by the disruption caused due to Covid'19. Going forward, with 10 expected launches in H1FY21 in the US market, strong ramp up in the domestic sales with major focus on prescription driven sales and 15% expected growth in API sales over FY20 – we expect a strong traction in FY21. The long term prospects of the company looks promising based on the commissioning of the new facilities (complex generics), for which the meaningful contribution is expected from FY22 onwards. Though the margins will be under pressure due to increase in R&D cost and operational cost on account of commissioning of these new facilities. Therefore, we maintain our ACCUMULATE rating on the stock with the target price of Rs.780.



Stock In News

Moody's slashes India growth forecast to 0.2% for 2020-21: Moody's Investors Service on Tuesday slashed India growth forecast for calendar year 2020 to 0.2 percent, from 2.5 percent projected in March. For 2021, Moody's expects India's growth to rebound to 6.2 percent. In its report titled - Global Macro Outlook 2020-21 (April 2020 update), Moody's has lowered G-20 advanced economies as a group to contract by 5.8 percent in 2020 Moody's said the economic costs of coronavirus crisis amid the near shutdown of the global economy are accumulating rapidly.
Banks Write Off Over Rs 68,000 Crore Loans: Indian banks have technically written off a staggering amount of Rs 68,607 crore due from 50 top wilful defaulters, including absconding diamantaire Mehul Choksi, according to a reply under RTI from the Reserve Bank of India (RBI).
Franklin Templeton India fiasco, SEBI may conduct special audit for abrupt closure of schemes: Market regulator Securities and Exchange Board of India (SEBI) may conduct a special audit of Franklin Templeton India after the company wound up six schemes abruptly. Through this special audit, SEBI aims to check if trustees and management have carried out their duty properly or if there were any lapses. The six schemes shut down by the asset management company (AMC) had over Rs 26,000 crore of fund holders' money. Among the six closed schemes, Franklin India ultra short-term fund was the largest with assets worth Rs 9,679 crore.
Federal-Mogul Goetze: Partially resumed operations at its Rajasthan Plant. PPAV Automotive: Resumes operations at its Rajasthan and Gujarat facilities. CG Consumer Electricals: Partially resumes operations at its Baddi plant.
Gabriel India: Resumed operations at its plants in Haryana, Himachal Pradesh and Maharashtra. NLC India: Commences production of coal in Odisha, four years after allocation. Coal will be used to meet the requirements of existing and future coal-fired power plants.
Spandana Sphoorty Financial: 79 percent of the total branches (794 out of 1,006) are present in the green zone and all of these have been operational since April 20. Borrower base has not been significantly impacted due to the rural focus. Most borrowers reached out to are willing to pay. Collected Rs 13.3 crore in the last one week despite tight restrictions in
operations. Biocon: The company along with Mylan has launched Fulphila in Canada. Fulphila is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia.

Red: Negative Impact **Green:** Positive Impact **Black:** Neutral.




Management Concall


AXISBANK Q4FY20 Concall Highlights

u	Management believes given the scale and longevity of the crisis almost every industry is expected to be impacted. Bank will continue to focus on the having adequate surplus liquidity, being prudent in management credit and operation risk, conserve capital and even sacrifice growth if required.
	Almost 75% of the collegues handling operations are working from home on distributed location. Over 96% of the ATM
_	have remain operational and 99% of the branches are operational. In retail banking The team of relationship manager
	and customer service officer, liability sales executives , retail lending team are interacting daily with 3 lakhs clients
	Currently the LCR stands well at 120% and bank is carrying excess SLR of over Rs 48000 Cr.
	Bank has provided for 350 acre land and the security receipts in the books.
Ч	During the quarter, the Bank has made provisions of 7,730 Cr including `3,000 Cr related to COVID; taking the overall
_	additional provisions held by the Bank to 5,983 Cr.
	PCR of bank has improved to 69% as at end of Q4FY20, compared to 60% for Q3FY20 and 62% for Q4FY19.
Ч	In respect of the retail side of the business book continues to remain largely secured and stands at 80% of the book
	dominated by vanilla homeloans at 35%. Retail unsecured portfolio stands at 20% of the retail book out of which 82% is
	from salaried segment which has very low default rate and 80% of the borrowers are existing customers of the bank. 67%
	of the salaried customers are from premium Multinational companies, corporates
	All of the incremental wholesale book growth in FY20 has come from the AAA and AA rated clients and book has also
	been diversified with loans to outside top 10 sectors. 80% of the wholesale book now has rating of A- and better, the 95%
	of the incremental advances last year were in the A- and above category. Exposure to top 20 borrower as percentage of
	tier 1 capital has come down to below 90%.
	In respect to commercial banking portfolio 85% of the portfolio is secured and majority of the balance is supply chain
	finance to well rated corporate. Book is spread across 120 locations and 35 broad sectors.
	Fee income growth is expected to Slowdown and provisions are expected to increase and further downgrades are
	expected in BB&Below book during FY21
	During the quarter 74% of the saving account opened were through tap banking,66% of the fixed deposits and 53% of
	new mutual fund were acquired digitally.
	The deal between the bank and the Max financial is subject to approval of regulatory authority.
	Customers opting for moratorium currently are around 10-12% in number and by value approximately 25-28%. The 2/3
	of customers have enough money to pay but they are conserving liquidity.
	SME book sinkage during the year is attributable to cautious stance to supply chain finance.
	Bank has not taken any relaxtion for the provisioning provided by the RBI in related to dispensation under june 7 2019
	circular. Bank has made entire 10% provision on all loans greater than 0 days default.
	Bank has reviewed its international book and has identified some stressed assets there, but all the exposure are part of
	bb and book. Bank over last one year has either shutdown or is in process of shutting down the honkong, shanghai,
	Colombo and now in process of shutting UK office.
	Bank has not given moratorium to any NBFC nor it has been approached barring MFI classified as NBFC.
	In calculation of moratorium provision bank has taken all the assets that would have been classified as NPA if there was
	no moratorium, all the assets which were more than 0 days overdue. If the moratorium was taken only on NPA the
	provision on moratorium required would only be 73 Cr, if taken at all greater than 0 days overdues requirement would be
	Rs 560 Cr. The cumulative covid provision was Rs 3000 Cr in additional to that Rs 475 Cr provision was on account of not
	taking RBI dispensation.
	On the SME side 85% of the book was SME 3 or better.





PARTICIPANT WISE OPEN INTEREST





MARKET MOVERS (1 MONTH CHANGE)







Result Calendar Q3FY20					
BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date
533096	ADANIPOWER	27-Apr-20	534758	CIGNITI	07-May-20
500425	AMBUJACEM	27-Apr-20	532175	CYIENT	07-May-20
540777	HDFCLIFE	27-Apr-20	532281	HCLTECH	07-May-20
532187	INDUSINDBK	27-Apr-20	500790	NESTLEIND	12-May-20
532663	SASKEN	27-Apr-20	500338	PRSMJOHNSN	12-May-20
532215	AXISBANK	28-Apr-20	539268	SYNGENE	12-May-20
532129	HEXAWARE	29-Apr-20	500002	ABB	13-May-20
538566	APOLLOTRI	30-Apr-20	500124	DRREDDY	13-May-20
531533	ECOM	30-Apr-20	505890	KENNAMET	13-May-20
500696	HINDUNILVR	30-Apr-20	526299	MPHASIS	13-May-20
540222	LAURUSLABS	30-Apr-20	532523	BIOCON	14-May-20
543187	POWERINDIA	30-Apr-20	532988	RANEENGINE	18-May-20
540673	SIS	30-Apr-20	500307	NIRLON	19-May-20
532755	TECHM	30-Apr-20	532987	RBL	19-May-20
511742	UGROCAP	30-Apr-20	532349	TCI	19-May-20
531225	XTGLOBAL	30-Apr-20	532661	RML	20-May-20
531869	SACHEMT	01-May-20	505800	RANEHOLDIN	27-May-20
540716	ICICIGI	02-May-20	524038	VENLONENT	30-May-20
533179	PERSISTENT	05-May-20	539447	BEARDSELL	25-Jun-20



Economic Calendar					
Country	Monday 27th April 2020	Tuesday 28th April 2020	Wednesday 29th April 2020	Thursday 30th April 2020	Friday 01st May 2020
us		Retail Inventories Ex Auto, Goods Trade Balance, CB Consumer Confidence	API Weekly Crude Oil Stock, GDP, Crude Oil Inventories, Fed Interest Rate Decision		Manufacturing PMI, U.S. Baker Hughes Total Rig Count
UK/EUROPE				CPI, GDP, Unemployment Rate, ECB Interest Rate Decision	
INDIA					Holiday India - Maharashtra Day, FX Reserves, USD

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

<u>Disclosures</u>: Narnolia Financial Advisors Ltd. (NFAL) (FormerlyMicrosec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFALis engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority. NFAL, it's associates, Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report, NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month, period, NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have; a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report, d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and it's associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking, Investment Banking or Brokerage service transactions. Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement-

Analyst's ownership of the stocks mentioned in the Report	NIL

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 | Narnolia Commerze Limited (Formerly Microsec Commerze Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 | NarnoliaVelox Advisory Ltd.- SEBI Registered PMS: INP000005109 | Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 | Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 | Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 | Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:B.05.02568.

Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL)and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should con

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.